Skip to main content

Table 2 Single-nucleotide polymorphisms associated with breast cancer risk with P values of less than 0.01a

From: The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort

  All subjects Premenopausal Postmenopausal  
Locus WW
ca/co
WV
ca/co
VV
ca/co
OR
(95% CI)
P PACTb WW
ca/co
WV
ca/co
VV
ca/co
OR
(95% CI)
P PACTb WW
ca/co
WV
ca/co
VV
ca/co
OR
(95% CI)
P PACTb P int
SLCO1B1                    
rs11045773 898/857 401/468 50/67 0.83
(0.72-0.94)
0.0047 0.088 227/206 118/127 18/13 0.94
(0.72-1.21)
0.61 1.00 659/636 273/332 29/54 0.77
(0.65-0.90)
0.0009 0.020 0.17
rs11045777 899/855 401/471 50/64 0.83
(0.73-0.95)
0.0053 0.099 227/204 118/129 18/11 0.94
(0.73-1.22)
0.66 1.00 660/636 273/333 29/53 0.77
(0.65-0.90)
0.0009 0.019 0.17
rs976754 1,126/1,207 217/183 8/5 1.27
(1.03-1.55)
0.018 0.26 309/294 50/51 5/2 1.04
(0.71-1.53)
0.76 1.00 795/894 164/127 3/3 1.40
(1.10-1.79)
0.0046 0.077 0.15
rs16923519 836/921 452/421 62/53 1.17
(1.02-1.33)
0.018 0.26 244/222 107/114 12/11 0.92
(0.70-1.20)
0.53 1.00 577/685 335/297 50/42 1.26
(1.08-1.47)
0.0019 0.038 0.029
rs4149057 496/569 641/638 209/186 1.14
(1.02-1.27)
0.021 0.28 152/133 164/172 48/42 0.96
(0.77-1.19)
0.70 1.00 334/429 466/453 157/140 1.22
(1.07-1.39)
0.0024 0.046 0.047
rs4149058 778/854 468/467 95/72 1.15
(1.02-1.30)
0.029 0.34 220/204 122/120 21/22 0.94
(0.73-1.20)
0.66 1.00 541/636 342/337 71/50 1.23
(1.07-1.43)
0.0043 0.074 0.052
rs11045884 880/871 412/452 41/63 0.86
(0.75-0.99)
0.031 0.36 216/220 126/107 15/16 1.09
(0.84-1.42)
0.42 1.00 649/638 277/335 25/46 0.78
(0.66-0.92)
0.0023 0.044 0.033
rs11045825 953/943 357/394 38/55 0.87
(0.75-1.00)
0.045 0.45 237/236 112/97 14/13 1.09
(0.83-1.42)
0.54 1.00 700/692 237/288 23/42 0.79
(0.66-0.93)
0.0040 0.068 0.037
rs10841767 889/874 411/451 49/67 0.88
(0.77-1.00)
0.049 0.47 221/222 125/107 17/18 1.07
(0.83-1.38)
0.51 1.00 653/639 277/334 31/48 0.80
(0.69-0.94)
0.0059 0.091 0.058
rs11045813 917/918 372/401 37/56 0.88
(0.76-1.01)
0.068 0.58 225/229 118/99 13/12 1.12
(0.85-1.47)
0.40 1.00 677/676 245/293 23/44 0.79
(0.67-0.94)
0.0051 0.082 0.024
HSD17B4                    
rs382719 393/457 672/685 275/241 1.16
(1.04-1.29)
0.0084 0.097 105/124 179/172 76/51 1.32
(1.06-1.64)
0.012 0.12 282/329 479/499 194/184 1.11
(0.98-1.26)
0.11 0.657 0.16
rs17388769 919/1,002 393/364 33/21 1.21
(1.04-1.41)
0.012 0.13 243/258 108/89 11/0 1.56
(1.15-2.13)
0.004 0.051 656/729 280/266 22/21 1.12
(0.94-1.34)
0.15 0.77 0.074
  1. aSingle-nucleotide polymorphisms associated with breast cancer risk with P values of less than 0.01 (uncorrected for multiple testing) in either overall analyses or subgroup analyses of premenopausal or postmenopausal women. The odds ratios (ORs) and 95% confidence intervals (CIs) were based on conditional logistic regression models stratified by age group (within 5-year age groups) and specimen collection centers - the Cancer Prevention Institute of California, the University of Southern California, and the University of California at Irvine - using log-additive genetic models. bPACT (P value adjusted for correlated tests) within each gene was calculated by using the methods of Conneely and Boehnke [68]. When PACT values were applied across all genes evaluated, none of the values was statistically significant. c P values for interaction.
  2. CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.